Publicly available financial reports and market valuation data

Alumis Announces $316 Million IPO, Seeks $1 Billion Valuation

Jun 24, 2024, 02:50 PM

Alumis, an immunology biotech company, has announced its initial public offering (IPO) of 17.65 million shares priced between $16 and $18 per share. The company aims to raise $300 million through this IPO, which will support its TYK2 inhibitor through phase 3 psoriasis trials. Alumis is seeking a valuation of up to $1 billion in the US market. The proceeds from the planned IPO, tagged at $316 million, will also help fund a late-stage clinical trial for psoriasis.